These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3857047)

  • 1. Decreased number of PGD2 binding sites on platelets from patients with type IIa hyperlipoproteinemia.
    Abbate R; Modesti PA; Fortini A; Lombardi A; Matucci M; Gensini GF; Neri Serneri GG; Fellin R; Valerio G; Crepaldi G
    Atherosclerosis; 1985 Feb; 54(2):167-75. PubMed ID: 3857047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of type IIa, IIb and IV-hyperlipoproteinemia on platelet prostaglandin sensitivity, plasma thromboxane B2 and platelet half-life.
    Strobl-Jäger E; Widhalm K; Sinzinger H
    Prostaglandins Leukot Med; 1986 Nov; 25(1):39-47. PubMed ID: 3540998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization of prostaglandin-activated platelet adenylate cyclase.
    Cooper B; Schafer AI; Puchalsky D; Handin RI
    Prostaglandins; 1979 Apr; 17(4):561-71. PubMed ID: 461820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis.
    Cooper B
    Blood; 1979 Sep; 54(3):684-93. PubMed ID: 380688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered lipid composition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia.
    Prisco D; Rogasi PG; Paniccia R; Coppo M; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1988 Jun; 50(5):593-604. PubMed ID: 3413721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
    Hamid S; Whittle BJ
    Br J Pharmacol; 1985 May; 85(1):285-90. PubMed ID: 2992652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
    Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
    Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
    Virgolini I; Koller E; Li S; Yang Q; Banyai M; Rauscha F; Pidlich J; Pirker W; Sinzinger H
    Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
    Cooper B; Ahern D
    J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P; Kaliman J; Sinzinger H
    Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
    Hamid-Bloomfield S; Whittle BJ
    Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet prostaglandin D2 dehydrogenase in patients with myeloproliferative disorders.
    Sugiyama T; Okuma M; Uchino H
    Prostaglandins Leukot Med; 1986 Feb; 21(2):207-20. PubMed ID: 3457389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered platelet deformability in patients with type IIa and type IV hyperlipoproteinemia.
    Smith CM; Burris SM; Hunninghake DB; White JG
    Am J Hematol; 1988 Apr; 27(4):247-52. PubMed ID: 3354559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia.
    Shattil SJ; Bennett JS; Colman RW; Cooper RA
    J Lab Clin Med; 1977 Feb; 89(2):341-53. PubMed ID: 188956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Functional status of thrombocytes and the anti-aggregative activity of the vascular wall in dyslipoproteinemias and ischemic heart disease].
    Mikhailova IA; Lipovetskiĭ BM; Magracheva EIa; Gurevich VS
    Ter Arkh; 1989; 61(2):101-4. PubMed ID: 2727909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
    Gresele P; Deckmyn H; Huybrechts E; Vermylen J
    Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW; Maderna P; Accomazzo MR; Nicosia S; Tremoli E
    Biochem Pharmacol; 1989 Jan; 38(1):39-45. PubMed ID: 2462881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.